DexCom, Inc. (DXCM) Tax Rate: 23.16%
Is DexCom, Inc.’s tax rate high or low?
DexCom, Inc.'s tax rate of 23.16% is 645% above its 5-year average of -4.25%, near the high end of its 5-year range (-119.38%–23.78%).
10.58% above its 12-month average of 20.95%.
DXCM Tax Rate Chart
DXCM Average Tax Rate Chart
DXCM Current vs Average Tax Rate Chart
DXCM Tax Rate Metrics
TAX RATE
23.16%
TAX RATE AVG TTM
20.95%
TAX RATE AVG 3Y
19.59%
TAX RATE AVG 5Y
-4.25%
TAX RATE AVG 10Y
-2.50%
TAX RATE AVG 15Y
-2.71%
TAX RATE AVG 20Y
2.49%
CURRENT VS TTM AVG
+10.58%
CURRENT VS 3Y AVG
+18.22%
CURRENT VS 5Y AVG
+645.37%
CURRENT VS 10Y AVG
+1026.06%
CURRENT VS 15Y AVG
+955.40%
CURRENT VS 20Y AVG
+829.76%
DexCom, Inc. Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. Tax Rate FAQ
- What is the tax rate for DexCom, Inc. (DXCM)?
- The tax rate for DXCM stock is 23.16%.
- Is DexCom, Inc.'s tax rate high or low?
- DexCom, Inc.'s tax rate of 23.16% is 645% above its 5-year average of -4.25%, near the high end of its 5-year range (-119.38%–23.78%).
- What is the TTM average tax rate for DexCom, Inc. (DXCM)?
- The TTM average tax rate for DXCM stock is 20.95%.
- What is the 3Y average tax rate for DexCom, Inc. (DXCM)?
- The 3Y average tax rate for DXCM stock is 19.59%.
- What is the 5Y average tax rate for DexCom, Inc. (DXCM)?
- The 5Y average tax rate for DXCM stock is -4.25%.
- What is the 10Y average tax rate for DexCom, Inc. (DXCM)?
- The 10Y average tax rate for DXCM stock is -2.50%.
- What is the 15Y average tax rate for DexCom, Inc. (DXCM)?
- The 15Y average tax rate for DXCM stock is -2.71%.
- What is the 20Y average tax rate for DexCom, Inc. (DXCM)?
- The 20Y average tax rate for DXCM stock is 2.49%.
DexCom, Inc. Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2025-12-31 | 23.16% |
| 2024-12-31 | 18.73% |
| 2023-12-31 | 23.78% |
| 2022-12-31 | 12.69% |
| 2021-12-31 | 15.54% |
| 2020-12-31 | -119.38% |
| 2019-12-31 | 2.98% |
| 2018-12-31 | -0.47% |
| 2017-12-31 | -3.29% |
| 2016-12-31 | -1.08% |
| 2015-12-31 | -0.17% |
| 2014-12-31 | -0.45% |
| 2013-12-31 | 0.00% |
| 2012-12-31 | 2.33% |
| 2011-12-31 | 0.22% |
| 2010-12-31 | -17.91% |
| 2009-12-31 | 0.00% |
| 2008-12-31 | -4.27% |
| 2007-12-31 | 0.00% |
| 2006-12-31 | 0.00% |
| 2005-12-31 | 99.90% |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach